About Plenitude
Our Mission
Plenitude Pharma Inc exists to address one of healthcare’s most persistent challenges: critical drug shortages. We focus on developing essential medicines where patient need is high and availability has failed — ensuring that clinicians, hospitals, and communities have reliable access to the treatments they depend on every day.
We bring together scientific discipline, regulatory insight, and a commitment to efficiency to deliver sustainable solutions for healthcare systems.
Our Story
Plenitude was founded to meet a growing and urgent need across healthcare. Rising shortages, fragmented supply chains, and diminishing economic incentives have created gaps in availability for essential medicines. Our team recognized a clear opportunity: to rebuild a dependable supply of high-impact therapies by combining strategic product selection with streamlined development pathways.
Today, Plenitude is building a focused pipeline of shortage medicines designed to strengthen healthcare delivery and generate meaningful social and economic value.
Our Approach
- Identify Need — Continuous monitoring of FDA shortage lists and validated clinical demand.
- Select Strategically — Prioritizing essential medicines with high impact and low clinical risk.
- Plan Efficiently — Applying bioequivalence-led development planning and clear regulatory pathways.
- Support Continuity — Working with experienced partners to help strengthen long-term supply resilience.
Our approach is designed to reduce uncertainty, support informed decision-making, and contribute to long-term healthcare system resilience.
Leadership
Sarah Norring PhD – Director
Sarah brings extensive experience across the pharmaceutical and life sciences landscape, with a focus on regulatory affairs, development planning, and strategic leadership. She has worked across multiple stages of the product lifecycle, contributing to programs that require careful regulatory alignment and disciplined execution.
Her work is grounded in a strong understanding of healthcare systems, regulatory frameworks, and the responsibilities involved in stewarding essential medicines responsibly.
Alia Minhas MSc (Oxon) MBA ACSI – Director
Alia is an experienced executive with a background spanning private equity, investment banking, and strategic growth within the healthcare and life sciences sectors. She brings financial oversight, governance experience, and strategic perspective to Plenitude’s long-term direction.
Her career has focused on supporting organizations through complex growth environments, with an emphasis on operational rigor, capital discipline, and alignment between strategy and execution.
Advisory & Supporting Team
Plenitude is supported by experts in:
- regulatory affairs
- clinical development
- manufacturing and CMO partnerships
- legal and compliance
- commercial strategy
Our advisors bring decades of collective experience across regulatory affairs, clinical development, and supply strategy, ensuring our work is grounded in scientific excellence and regulatory discipline.
Looking ahead
Plenitude is focused on building a thoughtful, disciplined foundation to address essential medicine shortages over time. As the company evolves, we remain committed to transparency, collaboration, and the responsible stewardship of essential medicines.
If you would like to learn more about Plenitude or get in touch with the team, we welcome the conversation.